Table 6.

Proposed recommendations for myeloproliferative neoplasms in COVID afflicted areas/hospitals

Chronic myeloid leukemia	High priority	Continue TKI in accordance to standard guidelines Single agent 2nd generation TKI or reduced intensity protocols for blast crises (steroid + vincristine + TKI  for lymphoid BC and HMA/LDAC + TKI for myeloid BC) [53]
	Intermediate priority	Allogeneic transplants for advanced phase CML maybe deferred TFR trials may be deferred
	Low priority	Reduce follow up; BCR ABL monitoring  may  be done yearly in patients in MMR
Myeloproliferative neoplasms	Moderate priority	Decrease frequency of phlebotomy; may consider hydroxyurea for low risk polycythemia vera [60] Defer starting of JAK inhibitors [54] Postpone all allogeneic transplants
	Low priority	Reduce monitoring and increase follow up intervals